# SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

I Background Information:

A 510(k) Number K202423   
B Applicant Beckman Coulter, Inc.   
C Proprietary and Established Names MicroScan MICroSTREP plus Panels with Tetracycline

$( 0 . 0 6 \mathrm { - } 1 6 ~ \mu \mathrm { g / m L } )$

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LTT, JWY, LRG, JTZ,LTW</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.1640 -AntimicrobialSusceptibility Test Powder</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Review Summary:

This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II device requiring 510(k). The following items are present and acceptable.

1. The name and 510(k) number of the SUBMITTER'S previously cleared device. 2. Submitter's statement that the INDICATIONS FOR USE/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use. 3. A description of the device MODIFICATION(S), in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. This change was for reanalysis of MIC results for Streptococcus pneumoniae with tetracycline using currently recognized interpretive criteria. 4. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including, labeling, intended use, and physical characteristics.

5. A Design Control Activities Summary which includes:

a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.   
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied.

Table 1. Performance. Re-analysis of Results Obtained with S. pneumoniae/ Tetracycline with Currently-Recognized Interpretive Criteria   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Tot</td><td rowspan=1 colspan=1>EANbb</td><td rowspan=1 colspan=1>EA%b</td><td rowspan=1 colspan=1>CATot</td><td rowspan=1 colspan=1>CA%</td><td rowspan=1 colspan=1>No.R</td><td rowspan=1 colspan=1>No.S</td><td rowspan=1 colspan=1>min</td><td rowspan=1 colspan=1>maj</td><td rowspan=1 colspan=1>vmj</td></tr><tr><td rowspan=1 colspan=1>Manual Reada</td><td rowspan=1 colspan=1>296</td><td rowspan=1 colspan=1>267</td><td rowspan=1 colspan=1>90.2</td><td rowspan=1 colspan=1>295</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>WalkAway</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>98.1</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

a Primary method b Not evaluated in re-analysis but provided for context

Table 2. Quality Control. Re-analysis of QC Results Using Currently Recommended Range, Turbidity Inoculation Methoda   

<table><tr><td rowspan=1 colspan=1>Organism</td><td rowspan=1 colspan=1>Concentration(μg/mL)</td><td rowspan=1 colspan=1>Reference</td><td rowspan=1 colspan=1>Manual Read</td><td rowspan=1 colspan=1>WalkAway</td></tr><tr><td rowspan=9 colspan=1>S. pneumoniaeATCC 49619ExpectedRange: 0.06-0.5μg/mL</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>cYanmaGellowb</td><td rowspan=1 colspan=1>cYanmaGYllob</td><td rowspan=1 colspan=1>cYanmaGelowb</td></tr><tr><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>cYanmaGYellowb</td><td rowspan=1 colspan=1>cYanmaGYellowb</td></tr><tr><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

a Note CLSI QC range for S. pneumoniae ATCC 49619 was modified from $0 . 1 2 - 0 . 5 \mu \mathrm { g / m L }$ to $0 . 0 6 - 0 . 5 \mu \mathrm { g / m L }$ after clearance of the original $5 1 0 ( \mathrm { k } ) \mathrm { s }$ (K020939 and K062923).

Table 3. Trending. Evaluation of Trending of S. pneumoniae Isolates   

<table><tr><td rowspan=1 colspan=1>Read Method</td><td rowspan=1 colspan=1>TotalEvaluableforTrending</td><td rowspan=1 colspan=1>≥1DilutionlowerNo. (%)</td><td rowspan=1 colspan=1>ExactNo. (%)</td><td rowspan=1 colspan=1>≥1DilutionHigherNo. (%)</td><td rowspan=1 colspan=1>PercentDifference (CI)</td><td rowspan=1 colspan=1>TrendingNoted</td></tr><tr><td rowspan=1 colspan=1>Manual</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>4 (1.7)</td><td rowspan=1 colspan=1>65 (27.9)</td><td rowspan=1 colspan=1>164 (70.4)</td><td rowspan=1 colspan=1>68.7% (62.0 to74.3)</td><td rowspan=1 colspan=1>Yesa</td></tr><tr><td rowspan=1 colspan=1>WalkAway</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>2 (5.9)</td><td rowspan=1 colspan=1>27 (79.4)</td><td rowspan=1 colspan=1>5 (14.7)</td><td rowspan=1 colspan=1>8.9% (-6.7 to24.8)</td><td rowspan=1 colspan=1>No</td></tr></table>

a Trending is addressed in a footnote to the performance table in the device labeling.

To support the implementation of changes to FDA-recognized susceptibility test interpretive criteria (i.e., breakpoints), this submission included a breakpoint change protocol that was reviewed and accepted by FDA. This protocol addresses future revisions to device labeling in response to breakpoint changes that are recognized on the FDA STIC webpage (https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm410971. htm). The protocol outlined the specific procedures and acceptance criteria that Beckman Coulter intends to use to evaluate the MicroScan MICroSTREP plus Panels with tetracycline (0.06 to 16 $\mu \mathrm { g / m L } )$ when revised breakpoints for tetracycline are published on the FDA STIC webpage. The breakpoint change protocol included with the submission indicated that if specific criteria are met, Beckman Coulter will update the tetracycline device label to include (1) the new breakpoints, (2) an updated performance section after re-evaluation of data in this premarket notification with the new breakpoints, and (3) any new limitations as determined by their evaluation.

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared device.